Participated · Series A · Dec 2025

Founded in 2020, Kimialys has created and commercializes an innovative chemistry-based platform that functionalizes surfaces such as nanoparticles, biopuces and electrodes for in-vitro diagnostic and analytical applications. By improving surface treatment, the company aims to boost the sensitivity and reliability of diagnostic tests. The newly raised capital will enable Kimialys to finalize the industrialization of its processes and scale up production capacity. It also plans to launch an initial catalog of ready-to-use kits, broadening its product offering. A portion of the funds will be directed toward intensifying international commercial efforts. Although specific revenue or user metrics are not disclosed, the Series A round indicates investor confidence in the company’s commercialization and growth trajectory.

Participated · Equity · Dec 2025

Hocoia is a mobile and connected health company founded by a physician and a team of engineers in Strasbourg. The startup operates a fleet of MédicoBus that visit municipalities and workplaces to provide on-site preventive care and diagnostics. In October 2025 it introduced the Mammobus, described as the world’s smallest mobile mammography truck, designed to make breast-cancer screening quick and accessible even in remote areas. Its units integrate medical equipment with digital tools for data collection and care coordination. With newly secured capital, the firm plans to expand nationwide, strengthen its territorial coverage, and deepen partnerships with local authorities and corporate clients. The funding will also accelerate the development of additional technological solutions. The company has not disclosed revenue, user numbers, or other financial performance metrics.

Participated · Series A · Oct 2025

Founded in 2019 and headquartered in Roscoff, SeaBeLife engineers dual-acting small molecules designed to block both necroptosis and ferroptosis, two regulated cell-death pathways that drive tissue damage in several acute and chronic diseases. Its lead candidates are SBL03 for dry age-related macular degeneration (with recent positive in-vivo data in geographic atrophy) and SBL01 for severe acute hepatitis, both addressing large unmet medical needs. The company plans to begin first-in-human clinical trials in 2026. SeaBeLife’s pipeline is positioned as a potentially transformative, first-in-class approach to organ protection, differentiating it from single-pathway competitors. To date, the firm has attracted €9 million in total funding through a mix of equity and public grants, including support from Bpifrance, SATT Ouest Valorisation, Biotech Santé Bretagne, and the Région Bretagne. The new capital strengthens its runway as the team prepares for a larger Series A round to finance clinical studies and expand development of its multi-target platform.

Participated · Equity · Sep 2025

Founded in 2023, France-based Byome Labs is a deep-tech company that analyzes skin, scalp, oral, and vaginal microbiomes to match consumers with the most suitable cosmetic products. Its flagship system, Byome Derma, can read a customer’s skin microbiome in-store without invasive hardware and instantly suggest optimal products, positioning the firm as an enabler of personalized retail experiences for major cosmetics brands. The company has compiled a proprietary database of more than 5,000 microbiome profiles and built its own AI to interpret this data. Industry players such as Clarins and Shiseido are already in advanced talks to deploy the kit once production begins. Byome plans to start industrial manufacturing of Byome Derma kits by the end of 2025, expand its R&D and commercial teams, and begin international rollout across Europe, the United States, and Asia in 2026. The startup is additionally backed by ecosystem supporters including Bpifrance (Deeptech), French Tech, Cosmetic Valley, École Polytechnique, Dev’Up Centre Val de Loire, and Village by CA. No revenue figures were disclosed in the article.

Participated · Seed · May 2024

Hephaistos-Pharma is a preclinical biotech developing ONCO-Boost, a first‑in‑class intravenous immunostimulant that targets the innate immune response to treat cancers non‑responding to current regimens. The company is focused on enabling treatment of metastatic and hard‑to‑treat indications. Led by CEO Frederic Caroff, Hephaistos uses a technology designed for intravenous administration to reach systemic disease. It plans to use the new funding to expand operations and accelerate R&D. Hephaistos is part of the SyStInn consortium, which received additional grant funding to support clinical evaluation of ONCO-Boost. The company has operations in Lyon, France and a subsidiary in Liège, Belgium. HEPHAISTOS-Pharma develops next-generation immunotherapies for cancer, with a lead candidate called ONCO-Boost targeting solid tumors, notably sarcoma. The company plans to use new funding to finance GMP transfer and to advance ONCO-Boost toward clinical development. Proceeds will enable industrialization of its manufacturing process and preparation for clinical phases. HEPHAISTOS also intends to open a new subsidiary in Liège, Wallonia to leverage local facilities and expertise, explore additional applications, and strengthen its pipeline. Frederic Caroff is CEO and co-founder.